EVFM Evofem Biosciences
- 0.013
- -0.001-4.71%
Evofem Biosciences News
Aditxt, Inc. Merger With Evofem Biosciences Falls Through
Express News | Aditxt Said On April 26 Received Notice From Evofem That Evofem Was Exercising Its Right To Terminate Merger Agreement As Result Of Co's Failure To Provide Initial Parent Equity Investment
Evofem Biosciences: Contractual Agreements Initiated and Terminated
Evofem Strengthens Phexxi Intellectual Property With New Composition of Matter Patent From USPTO
-- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In the Moment" Contraceptive Phexxi in the U
Evofem Biosciences Issues Update With Latest Presentation
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Biosciences 4Q Loss/Shr 44c >EVFM
Evofem Reports $18.2 Million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth q
Press Release: Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI With Medi-Cal
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal PR Newswire SAN DIEGO, March 20, 2024 -- Medi-Cal serves more than 15.4 million Californians --
For Women Using GLP-1 Receptor Agonists Who Take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel Is a Logical Solution to Help Prevent Unintended Pregnancy
Express News | 'France Becomes First Country to Explicitly Enshrine Abortion Rights in Constitution' -Washington Post Report
Evofem Biosciences Achieves 2023 Prelim Net Product Sales of $18.1M to $18.3M
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Biosciences(EVFM.US) Officer Sells US$4 in Common Stocks
$Evofem Biosciences(EVFM.US)$ Officer Zhang Yan sold 104 shares of Common Stocks on Jan 12, 2024 at an average price of $0.0385 for a total value of $4.Source: Announcement What is statement of change
Washington State HCA Removes Prior Authorization for Hormone-Free "In the Moment" Contraceptive PHEXXI Ahead of Huskies Vs. Wolverines Championship Game
Laidlaw & Co. Downgrades Evofem Biosciences to Hold
Laidlaw & Co. analyst Yale Jen downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold.
Evofem Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/13/2023 — Laidlaw & Co. Downgrades Buy → Hold 10/13/2022 426.32% Stifel $3 → $0.5 Downgrades Buy → Hol
Shareholder Alert: Ademi LLP Investigates Whether Evofem Biosciences, Inc. Has Obtained a Fair Price in Its Transaction With Aditxt
MILWAUKEE, Dec. 12, 2023 /PRNewswire/ -- Ademi LLP is investigating Evofem (OTCQB: EVFM) for possible breaches of fiduciary duty and other violations of law in its transaction with Aditxt. Click here
Shares of Aditxt, Evofem Surge on $100 Million Acquisition Deal
By Dean Seal Shares of Aditxt and Evofem Biosciences soared after the companies signed a $100 million acquisition deal. Aditxt's stock was up 85% at $7.03 in premarket trading, after having closed t
Aditxt to Acquire Women's Health Company Evofem Biosciences
Aditxt To Acquire Evofem in Consideration of the Issuance of a Combination of Common Stk and Preferred Stk, and the Assumption of Certain Senior Indebtedness, Having an Aggregate Amount of $100M >ADTX
Aditxt To Acquire Evofem in Consideration of the Issuance of a Combination of Common Stk and Preferred Stk, and the Assumption of Certain Senior Indebtedness, Having an Aggregate Amount of $100M >ADTX
Analysis
Price Target
No Data
